Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

Date: October 25, 2016
Pages: 286
Price:
US$ 5,650.00
License [?]:
Publisher: MarketsandMarkets
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: NE5571DF3C8EN
Leaflet:

Download PDF Leaflet

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021
The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021). Over the years, the nuclear medicine/radiopharmaceuticals market has witnessed various advancements in radiopharmaceuticals. The market is in its growth phase with an increasing number of radioisotope approvals for different clinical indications. Ra-223, I-131, and Y-90 ensured their leading position in the nuclear medicine therapeutic market.

Factors such as advances in radiotracers and increasing incidence and prevalence of cancer and cardiac ailments, introduction of alpha emitters for targeted cancer therapy, high demand for radiopharmaceuticals in emerging markets, upcoming radioisotopes, and increasing new product launches by industry players are expected to drive the nuclear medicine/radiopharmaceuticals market in the coming years. However, the shutdown of major nuclear reactors, which are the main source for radiopharmaceutical production, is a major challenge for the growth of the market.

In 2016, North America is expected to account for the largest share of the global nuclear medicine/radiopharmaceuticals market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). Asia-Pacific is projected to have the highest growth rate in the forecast period. Factors such as the increasing geriatric population and incidence of cardiovascular diseases & cancer in China & Japan, installation of PET scanners in India, and approval of radium (223Ra) dichloride by the therapeutic goods administration (TGA) in Australia are likely to propel the market in the Asia-Pacific region.

The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies (expansions; new product launches; marketing and promotion; agreements, collaborations, partnerships, and funding; patent approval to increase their market shares and establish a strong foothold in the global market.

In-depth interviews were conducted with CEOs, sales and marketing directors, other innovation and technology directors, and executives from various key organizations operating in the nuclear medicine/radiopharmaceuticals market
  • By Company Type: Tier 1: 32%, Tier 2: 39%, Tier 3: 29%
  • By Designation: Director Level: 38%, C-level: 28%, Others: 34%
  • By Region: North America: 30%, Europe: 27%, APAC: 33%, RoW: 10%
Some of the major players in the nuclear medicine/radiopharmaceuticals market include Cardinal Health Inc. (U.S.), Mallinckrodt plc (Ireland), GE Healthcare (U.K.), Lantheus Medical Imaging, Inc. (U.S.), Bayer AG (Germany), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), and IBA Molecular Imaging (Belgium).

Research Coverage:

The report provides detailed description of the radiopharmaceuticals used in diagnostics as well as for therapy across various regions. It aims at estimating the market size and future growth potential of this market across different segments such as type, application, procedural volume, and region. Additionally, the report includes an in-depth competitive analysis of the key players in the market along with their company profiles, SWOT analysis, recent developments, and key market strategies.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms to garner a greater market shares. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:
  • Market Penetration: Comprehensive information on the products and services offered by top players in the nuclear medicine/radiopharmaceuticals market. The report analyzes the nuclear medicine/radiopharmaceuticals market by type, application, procedural volume, and region
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the nuclear medicine/radiopharmaceuticals market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for nuclear medicine/radiopharmaceuticals across regions
  • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the nuclear medicine/radiopharmaceuticals market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, and distribution networks of the leading players in the nuclear medicine/radiopharmaceuticals market
1 INTRODUCTION

1.1 OBJECTIVES OF STUDY
1.2 MARKET DEFINITION
  1.2.1 MARKETS COVERED
  1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH METHODOLOGY STEPS
  2.1.1 RESEARCH DESIGN
  2.1.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    2.1.2.1 Secondary research
    2.1.2.2 Primary research
    2.1.2.3 Key industry insights
  2.1.3 KEY DATA FROM PRIMARY SOURCES
  2.1.4 KEY INSIGHTS FROM PRIMARY SOURCES
  2.1.5 MARKET SIZE ESTIMATION METHODOLOGY
  2.1.6 MARKET DATA VALIDATION AND TRIANGULATION
  2.1.7 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

3.1 INTRODUCTION
3.2 CONCLUSION

4 PREMIUM INSIGHTS

4.1 NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS: MARKET OVERVIEW
4.2 GEOGRAPHIC ANALYSIS: NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY PET APPLICATION (2016)
4.3 NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY TYPE (2016 VS. 2021)
4.4 GEOGRAPHICAL SNAPSHOT OF THE NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
  5.2.1 DRIVERS
    5.2.1.1 Investment through public-private partnerships is expected to modernize diagnostic imaging centers
    5.2.1.2 Alpha radioimmunotherapy (RIT)-based targeted cancer treatment
    5.2.1.3 Advances in radiotracers
    5.2.1.4 Increasing incidence and prevalence of cancer and cardiac ailments
  5.2.2 RESTRAINTS
    5.2.2.1 Shorter half-life of radiopharmaceuticals
    5.2.2.2 High cost of nuclear medicine equipment
  5.2.3 OPPORTUNITIES
    5.2.3.1 High demand in emerging markets
    5.2.3.2 Upcoming radioisotopes
    5.2.3.3 Use of radiopharmaceuticals in neurological applications
  5.2.4 CHALLENGES
    5.2.4.1 Shutdown of nuclear reactors

6 NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY TYPE

6.1 INTRODUCTION
6.2 DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS
  6.2.1 SPECT RADIOPHARMACEUTICALS
    6.2.1.1 Tc-99m
    6.2.1.2 Tl-201
    6.2.1.3 Ga-67
    6.2.1.4 I-123
    6.2.1.5 Other SPECT isotopes
  6.2.2 PET RADIOPHARMACEUTICALS
    6.2.2.1 F-18
    6.2.2.2 Rubidium-82
    6.2.2.3 Other pet isotopes
6.3 THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS
  6.3.1 BETA EMITTERS
    6.3.1.1 Iodine-131
    6.3.1.2 Y-90
    6.3.1.3 Sm-153
    6.3.1.4 Re-186
    6.3.1.5 Lu-177
    6.3.1.6 Other beta emitters
  6.3.2 ALPHA EMITTERS
    6.3.2.1 Ra-223
  6.3.3 BRACHYTHERAPY ISOTOPES
    6.3.3.1 Iodine-125
    6.3.3.2 Iridium-192
    6.3.3.3 Palladium-103
    6.3.3.4 Cesium-131
    6.3.3.5 Other brachytherapy isotopes

7 NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY APPLICATION

7.1 INTRODUCTION
7.2 DIAGNOSTIC APPLICATIONS
  7.2.1 SPECT APPLICATIONS
    7.2.1.1 Cardiology
    7.2.1.2 Neurology
    7.2.1.3 Thyroid
    7.2.1.4 Other SPECT applications
  7.2.2 PET APPLICATIONS
    7.2.2.1 Oncology
    7.2.2.2 Cardiology
    7.2.2.3 Neurology
    7.2.2.4 Other PET applications
7.3 THERAPEUTIC APPLICATIONS
  7.3.1 THYROID
  7.3.2 BONE METASTASIS
  7.3.3 LYMPHOMA
  7.3.4 ENDOCRINE TUMORS
  7.3.5 OTHER THERAPEUTIC APPLICATIONS

8 NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME

8.1 INTRODUCTION
8.2 DIAGNOSTIC PROCEDURES
  8.2.1 SPECT RADIOPHARMACEUTICALS
  8.2.2 PET RADIOPHARMACEUTICALS
8.3 THERAPEUTIC PROCEDURES
  8.3.1 BETA EMITTERS
  8.3.2 ALPHA EMITTERS
  8.3.3 BRACHYTHERAPY ISOTOPES

9 GLOBAL NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY REGION

9.1 INTRODUCTION
9.2 DIAGNOSTICS
  9.2.1 NORTH AMERICA
  9.2.2 U.S.
    9.2.2.1 Domestic production of Mo-99 in the U.S.
    9.2.2.2 Approval of new radiopharmaceuticals by the FDA
  9.2.3 CANADA
    9.2.3.1 Extension of operations at the Canadian NRU reactor
    9.2.3.2 Alternative medical isotope technologies in CANADA
9.3 EUROPE
  9.3.1 GERMANY
    9.3.1.1 New irradiation facility in GERMANY
  9.3.2 FRANCE
    9.3.2.1 Shutdown of the French Osiris nuclear reactor
  9.3.3 U.K.
    9.3.3.1 Increasing adoption of nuclear medicine equipment
  9.3.4 ITALY
    9.3.4.1 Steady growth in healthcare expenditure
  9.3.5 SPAIN
    9.3.5.1 Role of the SEMNIM in Spain
  9.3.6 REST OF EUROPE (ROE)
    9.3.6.1 Rapid rise in the geriatric population
9.4 ASIA-PACIFIC
  9.4.1 INSTALLATION OF PET SCANNERS IN INDIA
  9.4.2 INVESTMENT BY THE AUSTRALIAN GOVERNMENT
  9.4.3 INITIATIVES TO PROMOTE HEALTH
9.5 ROW
  9.5.1 IAEA INITIATIVES IN LATAM
  9.5.2 ARGENTINA’S INCREASING IRRADIATION CAPACITY

10 GLOBAL NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY REGION

10.1 THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET
  10.1.1 NORTH AMERICA
  10.1.2 U.S.
    10.1.2.1 FDA approval for alpha emitters
    10.1.2.2 Therapeutic nuclear medicine—alternative treatment choice in oncology
  10.1.3 CANADA
    10.1.3.1 Expertise in isotope production
    10.1.3.2 Government initiatives to increase the number of nuclear medicine treatment centers
  10.1.4 EUROPE
  10.1.5 GERMANY
    10.1.5.1 Radionuklidtherapeutika—a research program conducted in Germany
  10.1.6 FRANCE
    10.1.6.1 The FIRM project
  10.1.7 U.K.
    10.1.7.1 ‘A voice for radiotherapy’ initiative in the U.K.
  10.1.8 ITALY
    10.1.8.1 Growing incidence of cancer
  10.1.9 SPAIN
    10.1.9.1 Rising demand for radiotherapeutics
  10.1.10 ROE
    10.1.10.1 Government and public–private investment
    10.1.10.2 Research on cancer in Poland
  10.1.11 ASIA-PACIFIC
    10.1.11.1 Increasing aging population in Japan
    10.1.11.2 Aging population and increasing cancer prevalence in China
    10.1.11.3 Approval of Ra-223 dichloride by the TGA in Australia
  10.1.12 ROW
    10.1.12.1 Increase in cancer incidence

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS
  11.2.1 INTRODUCTION
  11.2.2 CARDINAL HEALTH, INC.
  11.2.3 MALLINCKRODT PLC
  11.2.4 GE HEALTHCARE
  11.2.5 BAYER HEALTHCARE
  11.2.6 LANTHEUS MEDICAL IMAGING, INC.
11.3 COMPETITIVE SITUATIONS AND TRENDS
  11.3.1 AGREEMENTS, PARTNERSHIPS, AND CONTRACTS
  11.3.2 MARKETING AND PROMOTIONAL ACTIVITIES
  11.3.3 EXPANSIONS
  11.3.4 ACQUISITIONS
  11.3.5 PRODUCT APPROVALS
  11.3.6 DIVESTMENTS
  11.3.7 PRODUCT LAUNCHES
  11.3.8 OTHER STRATEGIES

12 COMPANY PROFILES

(Overview, Products and Services, Financials, Strategy & Development)*

12.1 INTRODUCTION
12.2 CARDINAL HEALTH, INC.
12.3 MALLINCKRODT PLC
12.4 GE HEALTHCARE (A FULLY-OWNED SUBSIDIARY OF GENERAL ELECTRIC COMPANY)
12.5 LANTHEUS MEDICAL IMAGING, INC.
12.6 BAYER AG
12.7 BRACCO IMAGING S.P.A
12.8 ECZACIBASI-MONROL NUCLEAR PRODUCTS
12.9 NORDION, INC. (A SUBSIDIARY OF STERIGENICS INTERNATIONAL LLC.)
12.10 ADVANCED ACCELERATOR APPLICATIONS S.A.
12.11 IBA MOLECULAR

*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.

13 APPENDIX

13.1 INSIGHTS OF INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 OTHER DEVELOPMENTS
  13.3.1 CARDINAL HEALTH, INC.
  13.3.2 MALLINCKRODT PLC
  13.3.3 GE HEALTHCARE
  13.3.4 LANTHEUS MEDICAL IMAGING, INC.
  13.3.5 BAYER AG
  13.3.6 BRACCO IMAGING S.P.A
  13.3.7 ECZACIBASI-MONROL NUCLEAR PRODUCTS
  13.3.8 NORDION, INC.
  13.3.9 ADVANCED ACCELERATOR APPLICATIONS S.A.
  13.3.10 IBA MOLECULAR
13.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.6 AVAILABLE CUSTOMIZATIONS
13.7 RELATED REPORTS
13.8 AUTHOR DETAILS

LIST OF TABLES

Table 1 NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 2 DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 3 DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 4 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 5 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 6 SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 7 SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 8 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 9 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 10 TC-99M MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 11 NORTH AMERICA: TC-99M NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 12 EUROPE: TC-99M MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 13 TL-201 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 14 NORTH AMERICA: TL-201 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 15 EUROPE: THALLIUM-201 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 16 GA-67 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 17 NORTH AMERICA: GA-67 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 18 EUROPE: GA-67 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 19 I-123 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 20 NORTH AMERICA: I-123 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 21 EUROPE: I-123 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 22 OTHER SPECT ISOTOPES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 23 NORTH AMERICA: OTHER SPECT ISOTOPES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 24 EUROPE: OTHER SPECT ISOTOPES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 25 PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 26 PET RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 27 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 28 EUROPE: PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 29 F-18 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 30 NORTH AMERICA: F-18 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 31 EUROPE: F-18 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 32 RUBIDIUM-82 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 33 NORTH AMERICA: RUBIDIUM-82 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 34 EUROPE: RUBIDIUM-82 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 35 OTHER PET ISOTOPES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 36 NORTH AMERICA: OTHER PET ISOTOPES NUCLEAR MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 37 EUROPE: OTHER PET ISOTOPES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 38 THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 39 THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 40 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 41 EUROPE: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 42 BETA EMITTERS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 43 BETA EMITTERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 44 NORTH AMERICA: BETA EMITTERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 45 EUROPE: BETA EMITTERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 46 IODINE-131 MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 47 NORTH AMERICA: IODINE-131 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 48 EUROPE: I-131 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 49 Y-90 MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 50 NORTH AMERICA: Y-90 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 51 EUROPE: Y-90 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 52 SM-153 MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 53 NORTH AMERICA: SM-153 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 54 EUROPE: SM-153 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 55 RE-186 MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 56 NORTH AMERICA: RE-186 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 57 EUROPE: RE-186 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 58 LU-177 MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 59 NORTH AMERICA: LU-177 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 60 EUROPE: LU-177 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 61 OTHER BETA EMITTERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 62 NORTH AMERICA: OTHER BETA EMITTERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 63 EUROPE: OTHER BETA EMITTERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 64 RA-223 MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 65 NORTH AMERICA: RA-223 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 66 EUROPE: RADIUM-223 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 67 BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 68 BRACHYTHERAPY ISOTOPES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 69 NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 70 EUROPE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 71 I-125 MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 72 NORTH AMERICA: IODINE-125 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 73 EUROPE: IODINE-125 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 74 IRIDIUM-192 MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 75 NORTH AMERICA: IRIDIUM-192 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 76 EUROPE: IRIDIUM-192 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 77 PALLADIUM-103 MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 78 NORTH AMERICA: PALLADIUM-103 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 79 EUROPE: PD-103 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 80 CESIUM-131 MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 81 NORTH AMERICA: CESIUM-131 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 82 EUROPE: CESIUM-131 MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 83 OTHER BRACHYTHERAPY ISOTOPES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 84 NORTH AMERICA: OTHER BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 85 EUROPE: OTHER BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 86 SPECT APPLICATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 87 SPECT APPLICATIONS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 88 NORTH AMERICA: SPECT APPLICATIONS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 89 EUROPE: SPECT APPLICATIONS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 90 CARDIOLOGY APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 91 NORTH AMERICA: CARDIOLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 92 EUROPE: CARDIOLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 93 NEUROLOGY APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 94 NORTH AMERICA: NEUROLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 95 EUROPE: NEUROLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 96 THYROID APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 97 NORTH AMERICA: THYROID APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 98 EUROPE: THYROID APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 99 OTHER SPECT APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 100 NORTH AMERICA: OTHER SPECT APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 101 EUROPE: OTHER SPECT APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 102 PET APPLICATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 103 PET APPLICATIONS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 104 NORTH AMERICA: PET APPLICATIONS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 105 EUROPE: PET APPLICATIONS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 106 ONCOLOGY APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 107 NORTH AMERICA: ONCOLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 108 EUROPE: ONCOLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 109 CARDIOLOGY APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 110 NORTH AMERICA: CARDIOLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 111 EUROPE: CARDIOLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 112 NEUROLOGY APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 113 NORTH AMERICA: NEUROLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 114 EUROPE: NEUROLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 115 OTHER PET APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 116 NORTH AMERICA: OTHER PET APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 117 EUROPE: OTHER PET APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 118 THERAPEUTIC APPLICATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 119 THYROID APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 120 NORTH AMERICA: THYROID APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 121 EUROPE: THYROID APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 122 BONE METASTASIS APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 123 NORTH AMERICA: BONE METASTASIS APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 124 EUROPE: BONE METASTASIS APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 125 LYMPHOMA APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 126 NORTH AMERICA: LYMPHOMA APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 127 EUROPE: LYMPHOMA APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 128 ENDOCRINE TUMOR APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 129 NORTH AMERICA: ENDOCRINE TUMOR APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 130 EUROPE: ENDOCRINE TUMOR APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 131 OTHER THERAPEUTIC APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 132 NORTH AMERICA: OTHER THERAPEUTIC APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 133 EUROPE: OTHER THERAPEUTIC APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 134 NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME, 2014–2021 (THOUSAND UNITS)
Table 135 NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014–2021 (THOUSAND UNITS)
Table 136 DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (THOUSAND UNITS)
Table 137 DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014–2021 (THOUSAND UNITS)
Table 138 SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (THOUSAND UNITS)
Table 139 SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014–2021 (THOUSAND UNITS)
Table 140 PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (THOUSAND UNITS)
Table 141 PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (THOUSAND UNITS)
Table 142 THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (THOUSAND UNITS)
Table 143 THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014–2021 (THOUSAND UNITS)
Table 144 BETA EMITTER NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (THOUSAND UNITS)
Table 145 BETA EMITTER NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014–2021 (THOUSAND UNITS)
Table 146 ALPHA EMITTER NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014–2021 (THOUSAND UNITS)
Table 147 BRACHYTHERAPY ISOTOPES NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (THOUSAND UNITS)
Table 148 BRACHYTHERAPY ISOTOPES NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014–2021 (THOUSAND UNITS)
Table 149 GLOBAL NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 150 DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 151 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 152 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 153 NORTH AMERICA: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 154 NORTH AMERICA: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 155 NORTH AMERICA: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 156 NORTH AMERICA: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 157 U.S.: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 158 U.S.: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 159 U.S.: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 160 U.S.: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 161 U.S.: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 162 CANADA: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 163 CANADA: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 164 CANADA: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 165 CANADA: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 166 CANADA: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 167 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 168 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 169 EUROPE: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 170 EUROPE: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 171 EUROPE: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 172 EUROPE: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 173 GERMANY: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 174 GERMANY: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 175 GERMANY: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 176 GERMANY: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 177 GERMANY: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 178 FRANCE: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 179 FRANCE: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 180 FRANCE: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 181 FRANCE: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 182 FRANCE: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 183 U.K.: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 184 U.K.: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 185 U.K.: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 186 U.K.: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 187 U.K.: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 188 ITALY: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 189 ITALY: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 190 ITALY: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 191 ITALY: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 192 ITALY: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 193 SPAIN: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 194 SPAIN: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 195 SPAIN: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 196 SPAIN: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 197 SPAIN: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 198 ROE: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 199 ROE: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 200 ROE: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 201 ROE: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 202 ROE: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 203 ASIA-PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 204 ASIA-PACIFIC: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 205 ASIA-PACIFIC: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 206 ASIA-PACIFIC: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 207 ASIA-PACIFIC: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 208 ROW: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 209 ROW: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 210 ROW: SPECT NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 211 ROW: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 212 ROW: PET NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 213 THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 214 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 215 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 216 NORTH AMERICA: BETA EMITTERS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 217 NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 218 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 219 U.S.: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 220 U.S.: BETA EMITTERS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 221 U.S.: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 222 U.S.: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 223 CANADA: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 224 CANADA: BETA EMITTERS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 225 CANADA: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 226 CANADA: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 227 EUROPE: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 228 EUROPE: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 229 EUROPE: BETA EMITTERS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 230 EUROPE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 231 EUROPE: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 232 GERMANY: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 233 GERMANY: BETA EMITTERS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 234 GERMANY: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 235 GERMANY: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 236 FRANCE: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 237 FRANCE: BETA EMITTERS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 238 FRANCE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 239 FRANCE: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 240 U.K.: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 241 U.K.: BETA EMITTERS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 242 U.K.: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 243 U.K.: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 244 ITALY: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 245 ITALY: BETA EMITTERS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 246 ITALY: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 247 ITALY: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 248 SPAIN: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 249 SPAIN: BETA EMITTERS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 250 SPAIN: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 251 SPAIN: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 252 ROE: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 253 ROE: BETA EMITTERS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 254 ROE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 255 ROE: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 256 ASIA-PACIFIC: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 257 ASIA-PACIFIC: BETA EMITTERS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 258 ASIA-PACIFIC: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 259 ASIA-PACIFIC: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 260 ROW: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 261 ROW: BETA EMITTERS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 262 ROW: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 263 ROW: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 264 AGREEMENTS, PARTNERSHIPS, AND CONTRACTS (2013–2016)
Table 265 MARKETING AND PROMOTIONAL ACTIVITIES (2013–2016)
Table 266 EXPANSIONS (2013–2016)
Table 267 ACQUISITIONS (2013–2016)
Table 268 PRODUCT APPROVALS (2013–2016)
Table 269 DIVESTMENTS (2013–2016)
Table 270 PRODUCT LAUNCHES (2013–2016)
Table 271 OTHER STRATEGIES (2013–2016)

LIST OF FIGURES

Figure 1 GLOBAL NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SEGMENTATION
Figure 2 GLOBAL NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET: RESEARCH METHODOLOGY STEPS
Figure 3 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 4 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 5 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 6 DATA TRIANGULATION METHODOLOGY
Figure 7 GLOBAL NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET ANALYSIS, BY TYPE (2016 VS. 2021)
Figure 8 GLOBAL NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS DIAGNOSTIC APPLICATIONS MARKET SIZE, BY SPECT TECHNIQUE, 2016 VS. 2021 (USD MILLION)
Figure 9 ASIA-PACIFIC TO WITNESS THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 10 NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET IS PROJECTED TO WITNESS A HIGH CAGR IN THE FORECAST PERIOD
Figure 11 ONCOLOGY SEGMENT IS EXPECTED TO DOMINATE THE PET APPLICATIONS MARKET IN 2016
Figure 12 DIAGNOSTICS SEGMENT IS EXPECTED TO CONTINUE TO DOMINATE THE NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET UNTIL 2021
Figure 13 APAC IS EXPECTED TO WITNESS THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 14 NUCLEAR MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
Figure 15 DIAGNOSTICS SEGMENT IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET IN 2016
Figure 16 PET SEGMENT TO GROW AT THE HIGHER CAGR DURING THE FORECAST PERIOD
Figure 17 ALPHA EMITTERS SEGMENT IS EXPECTED TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 18 NEUROLOGY APPLICATIONS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 19 NEUROLOGY APPLICATIONS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 20 ENDOCRINE TUMORS APPLICATION SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 21 NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME (2016 VS. 2021)
Figure 22 NORTH AMERICA IS EXPECTED TO DOMINATE THE DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET IN 2016
Figure 23 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SNAPSHOT
Figure 24 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SNAPSHOT
Figure 25 ASIA-PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SNAPSHOT
Figure 26 ROW DIAGNOSTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SNAPSHOT
Figure 27 NORTH AMERICA IS EXPECTED TO DOMINATE THE THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET IN 2016
Figure 28 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SNAPSHOT
Figure 29 EUROPE: THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SNAPSHOT
Figure 30 ASIA-PACIFIC THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SNAPSHOT
Figure 31 ROW THERAPEUTIC NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SNAPSHOT
Figure 32 AGGREEMENTS, PARTNERSHIPS, AND CONTRACTS WERE THE KEY GROWTH STRATEGY ADOPTED BY MARKET COMPANIES BETWEEN 2013 AND 2016
Figure 33 NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET SHARE, BY KEY COMPANY (2015)
Figure 34 AGREEMENTS, PARTNERSHIPS, AND CONTRACTS ARE THE KEY GROWTH STRATEGY ADOPTED BY MARKET COMPANIES
Figure 35 AGREEMENTS, PARTNERSHIPS, AND CONTRACTS, BY COMPANY (2013–2016)
Figure 36 MARKETING AND PROMOTIONAL ACTIVITIES, BY COMPANY (2013–2016)
Figure 37 EXPANSIONS, BY COMPANY (2013–2016)
Figure 38 ACQUISITIONS, BY COMPANY (2013–2016)
Figure 39 PRODUCT APPROVALS, BY COMPANY (2013–2016)
Figure 40 DIVESTMENTS, BY COMPANY (2013–2016)
Figure 41 PRODUCT LAUNCHES, BY COMPANY (2013–2016)
Figure 42 OTHER STRATEGIES, BY COMPANY (2013–2016)
Figure 43 GEOGRAPHIC REVENUE MIX OF PROMINENT COMPANIES (2015)
Figure 44 CARDINAL HEALTH, INC.: COMPANY SNAPSHOT
Figure 45 MALLINCKRODT PLC: COMPANY SNAPSHOT
Figure 46 GE HEALTHCARE: COMPANY SNAPSHOT
Figure 47 LANTHEUS MEDICAL IMAGING, INC.: COMPANY SNAPSHOT
Figure 48 BAYER AG: COMPANY SNAPSHOT
Figure 49 ADVANCED ACCELERATOR APPLICATIONS S.A.: COMPANY SNAPSHOT
Skip to top


Ask Your Question

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: